CDK4 and breast carcinoma: Cyclin D1 acts as an oncogene in breast cancer by giving selective advantages to cancer cells, such as activation of its partner CDK4 and other cell cycle regulators for deregulating normal pathways and leading to abnormal cell cycle progression [24].